Company Overview
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company dedicated to the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions within the United States. The company functions within the Healthcare sector, specifically under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on advanced therapeutic compounds rather than mass-market generic pharmaceuticals. The organization maintains a workforce of 136 employees and holds a market capitalization of $1.51B. While the company has generated significant cash reserves, its annual revenue is not disclosed in the available financial data, which suggests the entity is still in a phase where capital expenditure for clinical trials exceeds current commercial sales. This valuation context indicates that the market capitalization is primarily driven by the potential value of its pipeline assets, specifically Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1, rather than current profit generation. The absence of reported revenue figures alongside a substantial market cap highlights the company's status as an asset-heavy biotech firm where investor sentiment is tied to future regulatory approvals and commercialization milestones rather than existing cash flows.
Financial Health
The company reports a net income of $-144,735,000 and an EBITDA of $-152,766,000, while revenue is not disclosed in the provided data. The significant negative net income relative to the reported EBITDA reveals a cost structure heavily influenced by non-operating expenses or interest costs that erode the operating earnings before interest, taxes, depreciation, and amortization. Free cash flow stands at $-66,994,876, indicating that the company is currently burning cash to fund its research and development activities, which limits immediate financial flexibility for share buybacks or aggressive debt repayment. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that indicates the company has not yet achieved commercial profitability or has not disclosed specific gross profit data, consistent with a pre-revenue or early-commercialization clinical-stage entity. On the balance sheet, the company holds $316.98M in cash against a total debt load of $5.96M, resulting in a debt-to-equity ratio of 1.95. Despite the high debt-to-equity figure, the balance sheet is fundamentally conservative due to the substantial cash cushion that vastly exceeds total obligations. The current ratio is listed at 14.27, which indicates an extremely strong position regarding short-term liquidity and the ability to meet immediate financial obligations without relying on external financing. Return on Equity is -61.6% and Return on Assets is -36.4%, metrics that reveal management has not yet generated positive returns on capital deployed, a common characteristic for clinical-stage firms but one that signals a high risk of value destruction if clinical programs fail.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is -11.15, a discrepancy that implies the market is pricing the stock based on expected future earnings that are currently projected to be negative. The price-to-book ratio is 4.92, which indicates that the market values the company at nearly five times its net asset book value, suggesting a high premium assigned to the intangible value of its drug pipeline. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -7.85, further complicate traditional valuation models due to the lack of positive earnings and sales data. The stock has traded with a 52-week high of $17.49 and a 52-week low of $3.11. Without a specific current price to calculate a precise percentage deviation, the trading range demonstrates significant volatility, with the stock capable of moving between a low of $3.11 and a high of $17.49 based on market conditions. The beta value is -0.30, a negative figure that suggests the stock's price moves inversely to the broader market or exhibits a unique decoupling from general market trends, which is an unusual characteristic for equities in the healthcare sector.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings velocity against revenue expansion. Since the earnings growth is negative and revenue is not disclosed, it is impossible to determine if earnings are growing faster or slower than revenue, though the negative net income suggests that costs are outpacing any current revenue generation. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of a payout ratio indicates that the company reinvests all available earnings, or in this case, utilizes its cash reserves, into growth initiatives such as clinical trials and regulatory filings rather than distributing income to shareholders. The overall growth and income profile is defined by a complete absence of current income distribution and disclosed growth rates, relying entirely on the successful execution of its clinical-stage drug development program to create future value.